World's largest, fully backward-integrated Ibuprofen maker; also produces APIs and specialty chemicals.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 57 | 59 | 59 | 59 | 59 | 59 | 59 | 59 |
| Reserves | 757 | 1.2k | 1.3k | 1.4k | 1.6k | 1.6k | 1.7k | 1.7k |
| Borrowings | 59 | 3 | 44 | 80 | 33 | 117 | 159 | 135 |
| Other Liabilities | 297 | 347 | 526 | 434 | 600 | 577 | 503 | 653 |
| Total Liabilities | 1.2k | 1.6k | 2.0k | 2.0k | 2.2k | 2.4k | 2.4k | 2.6k |
| AssetsFixed Assets | 469 | 512 | 561 | 751 | 933 | 1.2k | 1.1k | 1.2k |
| CWIP | 19 | 48 | 105 | 90 | 101 | 22 | 64 | 94 |
| Investments | 0 | 1 | 2 | 20 | 21 | 21 | 21 | 21 |
| Other Assets | 682 | 1.0k | 1.3k | 1.2k | 1.2k | 1.2k | 1.2k | 1.3k |
| Total Assets | 1.2k | 1.6k | 2.0k | 2.0k | 2.2k | 2.4k | 2.4k | 2.6k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 273 | 471 | 380 | 91 | 123 | 290 | 179 | 214 |
| Cash from Investing | -63 | -184 | -317 | -121 | -119 | -191 | -154 | -198 |
| Cash from Financing | -197 | -272 | -58 | -2 | -4 | -92 | 46 | -29 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 213 | 391 | 272 | -60 | -86 | 18 | -34 | 44 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (17.8×) and current (27.8×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At -0.5% growth and a 18× exit, ₹130 only delivers your return if you pay ₹34. The price is currently baking in 27% growth.
EPS grows -0.5%/yr for 5 years, then fades to 6% over 2, exits at 18×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | -0.5% | 4.67 |
| FY28 | -0.5% | 4.64 |
| FY29 | -0.5% | 4.62 |
| FY30 | -0.5% | 4.60 |
| FY31 | -0.5% | 4.57 |
| FY32 | 2.8% ·fade | 4.70 |
| FY33 | 6.0% ·fade | 4.98 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.